DoW Alzheimer’s Transforming Research Award

General Information Document Type: Grants Notice Funding Opportunity Number: HT942526AZRPTRRA Funding Opportunity Title: DoW Alzheimer’s Transforming Research Award Opportunity Category: Discretionary Opportunity Category Explanation: Funding Instrument Type: Grant Category of Funding Activity: Science and Technology and other Research and Development Category Explanation: Expected Number of Awards: 4 Assistance Listings: 12.420 -- Military Medical Research and Development Cost Sharing or Matching Requirement: No Version: Synopsis 1 Posted Date: May 01, 2026 Last Updated Date: May 01, 2026 Original Closing Date for Applications: Sep 24, 2026 Current Closing Date for Applications: Sep 24, 2026 Archive Date: Oct 24, 2026 Estimated Total Program Funding: $ 4,000,000 Award Ceiling: $ Award Floor: $ Eligibility Eligible Applicants: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility" Additional Information on Eligibility: Additional Information Agency Name: Defense Health Agency Contracting Activity - DHACA Description: Summary: The fiscal year 2026 (FY26) Alzheimer’s Research Program (AZRP) Transforming Research Award (TrRA) supports non-incremental, robust, well-designed research that drives transformative advancements in reducing risk and preventing the development of Alzheimer’s disease and/or Alzheimer's disease related dementias (AD/ADRD). Distinctive Features Applications must address at least one of the following focus areas: ○ Risk Factor Knowledge: Research that advances understanding, identification, and/or validation of risk and/or protective factors, with research outcomes/products focused on accelerating solutions. Projects may include, but are not limited to, research on environmental, epigenetic, genetic, lifestyle, occupational, or other risks not listed here. ○ Risk Reduction Solutions: Research that describes methods, technologies, and strategies that contribute to reducing risk and preventing AD/ADRD. Clinical research is allowed, however clinical trials and animal research are prohibited. Preliminary data are required. Community collaboration is required for research prospectively enrolling human subjects. Career Initiation or Transition (CIT) Partnership Option: The TrRA includes an option for more than one PI and supports both new and existing collaborative partnerships. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). If utilizing this option, at least one independent investigator must meet Link to Additional Information: Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact: eBRAP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org CDMRP Help Desk